Literature DB >> 1544671

The pathologic spectrum of the nephropathy associated with alpha 1-antitrypsin deficiency.

I D Davis1, B Burke, D Freese, H L Sharp, Y Kim.   

Abstract

To further define the clinicopathologic spectrum and pathogenetic mechanism of the nephropathy associated with alpha 1-antitrypsin (A1AT) deficiency, we evaluated renal specimens from 34 patients with chronic hepatic disease, including 20 with A1AT deficiency (study patients), and correlated these findings with urinalysis evaluation. Glomerular lesions were noted in 79% (15 of 19) of A1AT patients with the PiZZ phenotype, including seven with mesangio-capillary glomerulonephritis (MPGN and focal segmental MPGN), six with mesangial proliferative glomerulonephritis (Mes GN), one with diffuse endocapillary proliferative glomerulonephritis (DPGN), and one with focal segmental mesangial proliferative glomerulonephritis with segmental necrosis (FS Nec GN). One A1AT patient with the PiMZ phenotype did not demonstrate glomerular abnormalities. Focal segmental Mes GN was found in 43% (six of 14) of patients in an age-matched group with chronic hepatic failure unrelated to A1AT deficiency. In nine study patients, glomerular pathology was noted in the presence of a normal urinalysis. Immunofluorescence studies revealed the presence of immunoproteins and the A1AT protein isoelectric forms, PiM and PiZ, in the subendothelial region of glomerular basement membranes in A1AT patients with MPGN, Mes GN, and DPGN. Our results emphasize the heterogeneity of glomerular lesions associated with A1AT deficiency and hepatic disease and the relatively high incidence of MPGN in these children. The presence of abnormal PiZ protein in the subendothelial region of the glomerular basement membrane in A1AT patients with glomerulonephritis suggests a possible role for this protein in the pathogenesis of this lesion.

Entities:  

Mesh:

Year:  1992        PMID: 1544671     DOI: 10.1016/0046-8177(92)90012-r

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  Hidden burden of osteoporosis in alpha-1 antitrypsin deficiency.

Authors:  Emanuela Filipas; Iain Southern; Pooja Khanna; Ritwik Banerjee
Journal:  BMJ Case Rep       Date:  2018-06-27

Review 2.  Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history.

Authors:  M Needham; R A Stockley
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

3.  Glomerulonephritis as late manifestation of severe alpha 1-antitrypsin deficiency.

Authors:  R E Stauber; J H Horina; M Trauner; G J Krejs; M Ratschek; M Klimpfinger
Journal:  Clin Investig       Date:  1994-05

Review 4.  Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes.

Authors:  Sanjay H Chotirmall; Mazen Al-Alawi; Thomas McEnery; Noel G McElvaney
Journal:  Ther Clin Risk Manag       Date:  2015-01-29       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.